Peptides and Wellness: An Evidence-Based Reference Guide

Peptides appear in conversations about skin care, weight management, recovery and healthy ageing. Some are ingredients in medicines with established uses; others remain experimental. Understanding that difference is more useful than treating every product labelled “peptide” as equally safe or effective.

This guide explains the 13 substances and blends commonly discussed in this space, what the evidence can support, and which questions to take to a healthcare professional. It is general education, not a prescription, dosing guide or recommendation to buy or inject a product.

Understanding the evidence

Peptides are short chains of amino acids. However, not everything marketed alongside them is a peptide: NAD+ is a coenzyme, phosphatidylcholine is a lipid, deoxycholate is a bile-acid salt, and vitamin B12 is a vitamin. A shared marketing category does not mean a shared mechanism or safety profile.

Laboratory findings can explain how a substance might work. They do not establish that it improves health in people. Human trials must also be interpreted in context: the exact formulation, route, participants, outcomes and follow-up matter. A change in a blood marker is not automatically a meaningful improvement in symptoms or long-term health.

For South African readers, SAHPRA has warned about unregistered peptides promoted for weight loss, muscle growth, anti-ageing and injury recovery. Risks include contamination, infection, hormonal effects and unknown long-term consequences. A “research use only” label is not approval for human treatment. Ask a registered healthcare professional to check the exact product and its lawful access route. Overseas approval does not establish South African registration. [1]

The reference guide

1. Glutathione

Glutathione is a naturally occurring tripeptide involved in antioxidant defence. Its role inside the body does not prove that extra glutathione will detoxify the body, prevent infections or reverse ageing. A small randomised trial found that oral supplementation increased glutathione stores, so it is inaccurate to claim that all oral glutathione is simply destroyed and ineffective. That study did not establish broad clinical benefits. [3]

A subcutaneous injection goes into tissue beneath the skin, not directly into a vein. Injection does not automatically make a treatment safer or more effective. Injectable glutathione for skin lightening has attracted regulatory warnings, and contaminated preparations have caused serious reactions. [4] [5]

2. GLOW blends

“GLOW” is a marketing name rather than a standardised medicine. The formulation described here combines BPC-157, TB-500 and GHK-Cu; labels and strengths may vary. Claims that this mixture accelerates healing after cosmetic procedures should not be treated as established clinical benefits. FDA safety concerns about these ingredients also make reassurance about the blend inappropriate. [2]

3. GHK-Cu

GHK-Cu is a copper–peptide complex. Research or experience involving a topical preparation cannot establish the benefits or safety of an injectable version. The FDA identifies limited human safety data for injectable GHK-Cu and possible immune-reaction risks. Pen packaging does not resolve those uncertainties. [2]

4. Ipamorelin

Ipamorelin is studied for its ability to stimulate growth-hormone release. Early research demonstrating selective hormone effects was preclinical, not proof of improved sleep, body composition or healthy ageing in people. The FDA also identifies safety uncertainties for injectable use. [6] [2]

5. NAD+

Nicotinamide adenine dinucleotide is a coenzyme involved in cellular metabolism, not a peptide. A 2026 systematic review found that human health outcomes from NAD-related interventions were mixed and identified no eligible outcome trials of intravenous or intramuscular NAD+ itself for anti-ageing or wellness. Raising NAD-related markers should not be presented as proof of longer life, better cognition or improved energy. [7]

The FDA has received reports of severe chills, shaking, vomiting and fatigue following injectable NAD+ products and has warned about unsuitable ingredients and endotoxin contamination. Evidence for oral precursors cannot simply be transferred to injected NAD+. [8]

6. PPC and deoxycholate

Phosphatidylcholine and deoxycholate mixtures are discussed as “fat-dissolving” treatments, but they are not peptides. In the United States, approved deoxycholic acid injections have a specific indication for fat beneath the chin. This does not validate arbitrary PPC mixtures, treatment of other body areas, or weight-loss claims. FDA safety information describes potentially persistent injection-site reactions and warns about unapproved products. South African product status must be checked separately. [9]

7. Retatrutide

Retatrutide targets GIP, GLP-1 and glucagon receptors. Lilly’s October 2026 update describes it as an investigational medicine without regulatory approval. Trials are examining obesity, type 2 diabetes and related conditions. Promising trial findings do not turn an online vial into an approved treatment. [10]

Headline percentages depend on the study population, treatment duration and analysis used. They should not be presented as a guaranteed personal result or as proof that one treatment is superior to another without an appropriate direct comparison.

8. Tirzepatide

Tirzepatide acts at GIP and GLP-1 receptors and is used in prescription medicines. Aspen announced SAHPRA approval of Mounjaro for chronic weight management, alongside dietary and physical-activity measures, effective October 2025; it had previously launched for type 2 diabetes. This registration does not extend automatically to other products carrying the ingredient name. [11]

Clinical assessment remains essential. Prescribing information describes gastrointestinal side effects and warnings involving pancreatitis, gallbladder disease and dehydration-related kidney injury. It also includes contraindications involving medullary thyroid carcinoma and MEN2, plus relevant medicine interactions. A prescriber should use the current local product information and consider pregnancy, medical history and other treatments. Weight loss is variable and is not guaranteed. [12]

9. Wolverine Stack

“Wolverine Stack” usually describes BPC-157 with TB-500. Dramatic claims about repairing tendons, healing bowel disease or preventing reinjury are not established benefits of this combination. FDA concerns include limited safety information and peptide-related impurities; TB-500 should not automatically be equated with all thymosin beta-4 research. [2]

10. CJC-1295 and products labelled no DAC

The exact molecule matters when interpreting a CJC-1295 label. Do not transfer study findings between differently labelled formulations or assume a combination with another peptide is validated. The FDA reports limited clinical data and adverse events including increased heart rate and systemic vasodilation. [2]

11. Kisspeptin-10

Kisspeptin research concerns reproductive hormone signalling and sexual function. A small controlled study in men with low sexual desire used kisspeptin-54 under research supervision, not a retail kisspeptin-10 regimen. Those findings cannot establish claims of improved fertility, testosterone or mood from a different product. [13]

12. PT-141 or bremelanotide

The FDA-approved bremelanotide product, Vyleesi, has a narrow indication: acquired, generalised hypoactive sexual desire disorder in premenopausal women meeting specified criteria. Its label does not indicate use in men or for enhancing sexual performance. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea, blood-pressure effects and skin pigmentation changes are among its concerns. Claims of reliable prolonged arousal or established treatment of male erectile dysfunction go beyond this approval. Local registration must be verified separately. [14]

13. Lipo-C with vitamin B12

“Lipo-C” describes variable mixtures rather than a single standardised peptide medicine. The mixture in this guide includes methionine, inositol, choline and B12, sometimes with other ingredients. B12 deficiency can cause fatigue and warrants appropriate treatment, but NIH guidance states that extra B12 does not improve energy or endurance in people who already obtain enough. This should not be marketed as guaranteed fat loss or a solution to weight-loss plateaus. [15]

Questions to ask before considering treatment

Take the exact product name and ingredient list to a registered doctor or pharmacist. Ask:

What is my diagnosis, and what established alternatives are available?
Is this exact product registered for the proposed use, or is a specific lawful authorisation required?
Does the supporting research involve people, the same formulation and the same route?
What are the likely benefits, uncertainties, side effects and interactions for me?
Who will prescribe, supply and monitor treatment, and what follow-up is needed?

Avoid self-injecting products bought from unverified sources. Seek urgent medical care for breathing difficulty, collapse or severe symptoms following an injection. Suspected adverse reactions can also be reported through SAHPRA’s Med Safety reporting service. [1]

Editorial note: This article was adapted from a supplied reference guide and updated with linked regulatory and research sources on 29 October 2026. It has not been independently medically reviewed. It provides no dosing, mixing or injection instructions and does not endorse experimental products for human use. Regulatory information and evidence can change.